Source: Eur Respir Rev 2015; 24: 65-68
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Costabel Ulrich. The changing treatment landscape in idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 65-68

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Are the gains due to pulmonary rehabilitation in idiopathic pulmonary fibrosis and other interstitial lung diseases the same? Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 A first step against idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 130-131 Year: 2011 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The genetic basis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1717-1727 Year: 2015 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018 Comparison of clinical characteristics and prognosis in patients with idiopathic pulmonary upper lobe predominant pulmonary fibrosis and idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 48: 538-552 Year: 2016 The potential impact of azithromycin in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018 Year: 2019 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018